InvestorsHub Logo
Followers 0
Posts 157
Boards Moderated 0
Alias Born 04/28/2017

Re: cjarmstrong post# 2973

Friday, 11/17/2017 12:33:57 PM

Friday, November 17, 2017 12:33:57 PM

Post# of 6316
Having said that, Elsohly developed the transmucosal patch as a successor to the suppository, so I have no idea why Nemus is developing the suppository at all. I've said it before, but I believe it's something they should abandon. A patch or even buccal pill would be significantly more lucrative.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent SKYE News